Abstract
Purpose: Our aim was to assess the feasibility of bone marrow transplantation (BMT) in patients with acute leukemia who have had prior documented invasive fungal infection within 5 months pretransplant treated aggressively with systemic amphotericin B and, when applicable, surgical resection of the infected tissue. Materials and Methods: We reviewed the charts of patients with acute leukemia at our institution who underwent BMT between August 1992 and April 1994 after being treated for a severe fungal infection. We evaluated criteria for diagnosis of fungal infection, timing of infection in relation to BMT, and antifungal treatment modalities. We determined peritransplant complications, evidence for recurrence of fungal infection during BMT, morbidity related to antifungal drug therapy, and overall outcome in each patient. Results: Fungal infection developed in eight patients. Sites of involvement included lung, liver, spleen, and skin. All patients were treated with systemic amphotericin B. Some also underwent surgical resection of infected tissue following clinical control of infection. All patients underwent BMT. Seven of eight patients engrafted and survived BMT. One patient died of recurrent pulmonary mucormycosis. Three patients are alive and free of leukemia and fungal disease. Four patients died of noninfectious causes and had no evidence of fungal disease at the time of death. Conclusions: Aggressive therapy of prior fungal infection followed by ongoing anti-fungal prophylaxis in acute leukemia patients may allow BMT without reactivation of the fungus. Reports of larger series of such patients as well as studies of the efficacy of chemoprophylaxis of fungal infections are needed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 268-273 |
| Number of pages | 6 |
| Journal | Medical and Pediatric Oncology |
| Volume | 28 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 1997 |
Fingerprint
Keywords
- antifungal treatment modalities
- surgical resection
- systemic amphotericin B
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Oncology
- Cancer Research
Cite this
}
Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia. / Hoover, M.; Morgan, Elaine R; Kletzel, Morris.
In: Medical and Pediatric Oncology, Vol. 28, No. 4, 01.04.1997, p. 268-273.Research output: Contribution to journal › Article
TY - JOUR
T1 - Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia
AU - Hoover, M.
AU - Morgan, Elaine R
AU - Kletzel, Morris
PY - 1997/4/1
Y1 - 1997/4/1
N2 - Purpose: Our aim was to assess the feasibility of bone marrow transplantation (BMT) in patients with acute leukemia who have had prior documented invasive fungal infection within 5 months pretransplant treated aggressively with systemic amphotericin B and, when applicable, surgical resection of the infected tissue. Materials and Methods: We reviewed the charts of patients with acute leukemia at our institution who underwent BMT between August 1992 and April 1994 after being treated for a severe fungal infection. We evaluated criteria for diagnosis of fungal infection, timing of infection in relation to BMT, and antifungal treatment modalities. We determined peritransplant complications, evidence for recurrence of fungal infection during BMT, morbidity related to antifungal drug therapy, and overall outcome in each patient. Results: Fungal infection developed in eight patients. Sites of involvement included lung, liver, spleen, and skin. All patients were treated with systemic amphotericin B. Some also underwent surgical resection of infected tissue following clinical control of infection. All patients underwent BMT. Seven of eight patients engrafted and survived BMT. One patient died of recurrent pulmonary mucormycosis. Three patients are alive and free of leukemia and fungal disease. Four patients died of noninfectious causes and had no evidence of fungal disease at the time of death. Conclusions: Aggressive therapy of prior fungal infection followed by ongoing anti-fungal prophylaxis in acute leukemia patients may allow BMT without reactivation of the fungus. Reports of larger series of such patients as well as studies of the efficacy of chemoprophylaxis of fungal infections are needed.
AB - Purpose: Our aim was to assess the feasibility of bone marrow transplantation (BMT) in patients with acute leukemia who have had prior documented invasive fungal infection within 5 months pretransplant treated aggressively with systemic amphotericin B and, when applicable, surgical resection of the infected tissue. Materials and Methods: We reviewed the charts of patients with acute leukemia at our institution who underwent BMT between August 1992 and April 1994 after being treated for a severe fungal infection. We evaluated criteria for diagnosis of fungal infection, timing of infection in relation to BMT, and antifungal treatment modalities. We determined peritransplant complications, evidence for recurrence of fungal infection during BMT, morbidity related to antifungal drug therapy, and overall outcome in each patient. Results: Fungal infection developed in eight patients. Sites of involvement included lung, liver, spleen, and skin. All patients were treated with systemic amphotericin B. Some also underwent surgical resection of infected tissue following clinical control of infection. All patients underwent BMT. Seven of eight patients engrafted and survived BMT. One patient died of recurrent pulmonary mucormycosis. Three patients are alive and free of leukemia and fungal disease. Four patients died of noninfectious causes and had no evidence of fungal disease at the time of death. Conclusions: Aggressive therapy of prior fungal infection followed by ongoing anti-fungal prophylaxis in acute leukemia patients may allow BMT without reactivation of the fungus. Reports of larger series of such patients as well as studies of the efficacy of chemoprophylaxis of fungal infections are needed.
KW - antifungal treatment modalities
KW - surgical resection
KW - systemic amphotericin B
UR - http://www.scopus.com/inward/record.url?scp=0030908943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030908943&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1096-911X(199704)28:4<268::AID-MPO5>3.0.CO;2-G
DO - 10.1002/(SICI)1096-911X(199704)28:4<268::AID-MPO5>3.0.CO;2-G
M3 - Article
VL - 28
SP - 268
EP - 273
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
SN - 1545-5009
IS - 4
ER -